Artisan Partners Limited Partnership Boosts Stock Holdings in Celcuity, Inc. $CELC

Artisan Partners Limited Partnership lifted its position in Celcuity, Inc. (NASDAQ:CELC) by 45.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 585,892 shares of the company’s stock after purchasing an additional 184,214 shares during the period. Artisan Partners Limited Partnership owned about 1.38% of Celcuity worth $28,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Soleus Capital Management L.P. increased its holdings in Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after buying an additional 437,696 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Celcuity by 23.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after acquiring an additional 391,262 shares during the period. Eventide Asset Management LLC grew its position in shares of Celcuity by 9.8% during the 2nd quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after acquiring an additional 123,774 shares during the period. Saturn V Capital Management LP increased its stake in shares of Celcuity by 8.4% in the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after purchasing an additional 91,843 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in Celcuity by 27.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 768,796 shares of the company’s stock worth $10,263,000 after purchasing an additional 166,324 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CELC. Wells Fargo & Company began coverage on Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price target on the stock. Craig Hallum upped their target price on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Stifel Nicolaus boosted their price target on shares of Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, HC Wainwright restated a “neutral” rating and set a $94.00 price objective (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.25.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $111.71 on Friday. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. Celcuity, Inc. has a 1 year low of $7.57 and a 1 year high of $120.32. The firm has a market capitalization of $5.17 billion, a PE ratio of -30.44 and a beta of 0.36. The business’s 50 day moving average price is $106.46 and its 200-day moving average price is $82.73.

Insider Transactions at Celcuity

In other Celcuity news, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard E. Buller sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $105.69, for a total value of $317,070.00. Following the transaction, the director owned 6,760 shares in the company, valued at approximately $714,464.40. This represents a 30.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 15.77% of the stock is owned by corporate insiders.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.